Search

Tracking 15 key technologies, fraud in nanotechnology - and other insights into R&D management

A team of European researchers is applying a technology used to measure airflow over aircraft wings to improve human heart implants.

After the initial hype, the long haul through clinical development and the inevitable pitfalls, gene therapy is on the verge of becoming a commercial reality in Europe - ahead of the US.

The University of Cambridge is considering whether to make more cash available to invest in campus spin-off companies. And whatever decision it makes will come in for criticism…

Jo Taylor, head of venture capital at 3i Group, argues that universities are too quick to hit the spin-out button.

Universities are funding more campus companies. Richard L. Hudson on the rules of a very risky game.

Reports of incubators' demise were premature

For her latest fortnightly funding column, Mary Lisbeth D'Amico set out to find European seed funders. That was as easy as finding a needle in a haystack.

A spin-out from Sheffield that uses stem cells to help with conventional drug discovery is looking for investment to continue pre-clinical research on therapeutic applications and business development activities.

A spin-out from Sheffield University and Northwick Park Institute for Medical Research says it has created a compound using carbon monoxide that could save lives by helping with organ transplants.

The universities of Cambridge and Manchester, Imperial College London and the SETsquared Partnership, a joint venture among four universities in southern England, have won funding to collaborate with peers in the US and with companies such as Airbus and Boeing.

British drug-delivery company Phoqus blamed "unfavourable market" conditions for meeting only its minimum target of £10 million in its initial public offering.

The University of Manchester has signed an agreement with IBM to collaborate on research, teaching and recruitment.

Celoxica, an Oxford University spin-out that makes chip design software, blamed “depressive market” conditions for the company raising less capital than it initially expected in its initial public offering

CellCentric, a biotechnology company specialising in epigenetics, is to sponsor a collaboration in cancer research at the Wolfson Institute of Biomedical Research, University College London.

US biotechnology firm DOR BioPharma plans to build a bigger force in gastro-intestinal medicines by buying Copenhagen-based Gastrotech Pharma, a spin-out of Gothenburg University in Sweden.

A new research centre at Imperial Collegewill study urban energy efficiency and nuclear power generation.

Shares in Oxford BioMedica, an Oxford University spin-out, fell 8.3 percent on news that the company was seeking up to £30 million to fund the Phase III trial of its a TroVax cancer immunotherapy product.

"Basic research may seem very expensive. I am a well-paid scientist. My hourly wage is equal to that of a plumber..." Albert Szent-Györgyi, Nobel-winning chemist